Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Cannabinoid receptor as a novel target for the treatment of prostate cancer.

Sarfaraz S, Afaq F, Adhami VM, Mukhtar H.

Cancer Res. 2005 Mar 1;65(5):1635-41.

2.

Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent.

Sreevalsan S, Joseph S, Jutooru I, Chadalapaka G, Safe SH.

Anticancer Res. 2011 Nov;31(11):3799-807.

3.

Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.

Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE, Ganju RK.

Cancer Prev Res (Phila). 2011 Jan;4(1):65-75. doi: 10.1158/1940-6207.CAPR-10-0181. Epub 2010 Nov 19.

4.

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK.

Mol Cancer Ther. 2009 Nov;8(11):3117-29. doi: 10.1158/1535-7163.MCT-09-0448. Epub 2009 Nov 3.

5.

Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.

Liu Q, Bhat M, Bowen WD, Cheng J.

J Pharmacol Exp Ther. 2009 Dec;331(3):1062-70. doi: 10.1124/jpet.109.156216. Epub 2009 Sep 14.

6.

The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.

Morell C, Bort A, Vara D, Ramos-Torres A, Rodríguez-Henche N, Díaz-Laviada I.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):248-57. doi: 10.1038/pcan.2016.19. Epub 2016 Jun 21.

7.

Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.

Accorsi-Mendonça D, Almado CE, Dagostin AL, Machado BH, Leão RM.

Brain Res. 2008 Mar 20;1200:1-9. doi: 10.1016/j.brainres.2008.01.011. Epub 2008 Jan 16.

PMID:
18308297
8.

Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines.

Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, Pertwee RG, Heys SD.

Carcinogenesis. 2010 Sep;31(9):1584-91. doi: 10.1093/carcin/bgq151. Epub 2010 Jul 25.

9.

Cannabinoid receptor agonists modulate calcium channels in rat retinal Müller cells.

Yang W, Li Q, Wang SY, Gao F, Qian WJ, Li F, Ji M, Sun XH, Miao Y, Wang Z.

Neuroscience. 2016 Jan 28;313:213-24. doi: 10.1016/j.neuroscience.2015.11.039. Epub 2015 Nov 24.

PMID:
26621126
10.

Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.

Fernández-López D, Martínez-Orgado J, Nuñez E, Romero J, Lorenzo P, Moro MA, Lizasoain I.

Pediatr Res. 2006 Aug;60(2):169-73.

PMID:
16864698
11.

The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft.

Scuderi MR, Cantarella G, Scollo M, Lempereur L, Palumbo M, Saccani-Jotti G, Bernardini R.

Cancer Lett. 2011 Nov 28;310(2):240-9. doi: 10.1016/j.canlet.2011.07.008. Epub 2011 Jul 19.

PMID:
21807457
12.

Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.

González C, Herradón E, Abalo R, Vera G, Pérez-Nievas BG, Leza JC, Martín MI, López-Miranda V.

Diabetes Metab Res Rev. 2011 May;27(4):331-40. doi: 10.1002/dmrr.1176.

PMID:
21309057
13.

Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.

Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE.

Mol Pharmacol. 2006 Jul;70(1):41-50. Epub 2006 Mar 29.

14.
15.
16.

The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.

Abalo R, Cabezos PA, Vera G, Fernández-Pujol R, Martín MI.

Neurogastroenterol Motil. 2010 Jun;22(6):694-e206. doi: 10.1111/j.1365-2982.2009.01466.x. Epub 2010 Feb 3.

PMID:
20132133
17.

The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.

Luca T, Di Benedetto G, Scuderi MR, Palumbo M, Clementi S, Bernardini R, Cantarella G.

Eur J Pharmacol. 2009 Aug 15;616(1-3):16-21. doi: 10.1016/j.ejphar.2009.06.004. Epub 2009 Jun 17.

PMID:
19539619
18.

Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors.

Abalo R, Cabezos PA, Vera G, López-Miranda V, Herradón E, Martín-Fontelles MI.

Neurogastroenterol Motil. 2011 May;23(5):457-67, e177. doi: 10.1111/j.1365-2982.2011.01677.x. Epub 2011 Feb 8.

PMID:
21303434
19.

Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.

Mulè F, Amato A, Baldassano S, Serio R.

Pharmacol Res. 2007 Sep;56(3):185-92. Epub 2007 Jun 21.

PMID:
17656103
20.

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG.

Br J Pharmacol. 2007 Mar;150(5):613-23. Epub 2007 Jan 22.

Supplemental Content

Support Center